Greenleaf Trust Sells 5,677 Shares of Johnson & Johnson $JNJ

Greenleaf Trust lessened its position in Johnson & Johnson (NYSE:JNJ) by 6.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,318 shares of the company’s stock after selling 5,677 shares during the quarter. Greenleaf Trust’s holdings in Johnson & Johnson were worth $15,449,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $4,877,174,000. Bank of New York Mellon Corp lifted its holdings in shares of Johnson & Johnson by 2.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after acquiring an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Johnson & Johnson by 0.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock valued at $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Nipocalimab phase II success — JNJ reported nipocalimab met key endpoints in a Phase IIb SLE study, supporting a planned move to Phase III and de‑risking a late‑stage autoimmune program that could add future revenue. JNJ’s Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
• Positive Sentiment: MedTech growth catalyst — J&J MedTech submitted its Ottava surgical robot to the FDA, advancing a high‑margin growth avenue in robotics/surgery that could expand addressable market if cleared. Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Positive Sentiment: Research collaboration in cardiac gene therapy — JNJ is partnering with Lexeo Therapeutics to test localized AAV delivery using Impella technology, which could accelerate novel cardiac programs and strengthen cardiovascular R&D capabilities. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology
• Positive Sentiment: Analyst and media support — Barclays raised its JNJ price target (to $217) and Wolfe Research lifted its target to $240; high‑profile bullish commentary (Jim Cramer called it a “terrific entry point”) may attract buyers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs Wolfe Research Increases Johnson & Johnson Price Target to $240.00 Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”
• Neutral Sentiment: Innovative Medicines resilience — analysts note J&J’s Innovative Medicines segment remains resilient with key drugs offsetting some pressures; watch Q4 details for cadence and guidance. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch
• Neutral Sentiment: Macro tailwind for health care — sector rotation into health-care and dividend/value themes is supportive of JNJ stock but is a broader factor rather than company‑specific. Experts See Health Care’s Rally Continuing. This ETF Is Proof
• Negative Sentiment: Commercial headwinds — continued pressure from Stelara biosimilars and Medicare Part D dynamics could weigh on sales and near‑term margins in immunology/dermatology franchises. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of analyst reports. Scotiabank initiated coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price on the stock. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday, December 10th. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Guggenheim raised their price target on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Royal Bank Of Canada set a $240.00 price objective on Johnson & Johnson in a research report on Wednesday, December 17th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $212.62.

Johnson & Johnson Stock Down 0.8%

Shares of NYSE:JNJ opened at $205.78 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock’s 50-day moving average is $202.56 and its 200 day moving average is $184.15. The company has a market cap of $495.79 billion, a PE ratio of 19.86, a P/E/G ratio of 2.13 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.